FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1994855231> ?p ?o ?g. }

• W1994855231 endingPage "1289" @default.
• W1994855231 startingPage "1282" @default.
• W1994855231 abstract "Application of research-grade diagnostic kits in clinical drug development has grown commensurate with the increased interest in utilization of biomarkers as drug development tools. Since novel biomarkers are frequently macromolecular, immunoassay methodology comprises the ‘technology-of-choice’ for biomarker quantification. In particular, commercial research-grade immunoassay kits are appealing for use in biomarker quantification during clinical phase drug development because of their ready availability, ease of operation and perceived convenience. However, bioanalytical validation issues arise often during the application of commercial kits, as GLP regulatory-compliant application places greater demands on kit design and performance. In this review, we have used the receptor activator of nuclear factor κB ligand (RANKL) as a model system to offer some insights into the challenges that can be encountered in the application of ‘research-grade’ diagnostic kits in support of clinical drug development. Currently only a few assays are available commercially for the determination of circulating concentrations of sRANKL. Of these, two immunoassay designs have been most often. The first design employs human osteoprotegerin to capture unbound sRANKL from serum and, thereby, provides a measure of circulating free concentrations. In contrast, the other common assay design first involves preincubation of serum samples with human osteoprotegerin to convert the free fraction of sRANKL to the osteoprotegerin-bound complex. The bound fraction is subsequently captured by an anti-osteoprotegerin antibody. In both immunoassay designs, detection is accomplished with an anti-sRANKL enzyme conjugation system. In this report we review these sRANKL immunoassay designs critically from the perspective of their potential suitability as drug development biomarker tools. In addition, analytical challenges relevant to the application of these ‘research-grade’ diagnostic kits for regulatory-compliant determination of sRANKL concentrations are discussed." @default.
• W1994855231 created "2016-06-24" @default.
• W1994855231 creator A5022502699 @default.
• W1994855231 creator A5067344128 @default.
• W1994855231 date "2008-12-01" @default.
• W1994855231 modified "2023-10-02" @default.
• W1994855231 title "Insights in the application of research-grade diagnostic kits for biomarker assessments in support of clinical drug development: Bioanalysis of circulating concentrations of soluble receptor activator of nuclear factor κB ligand" @default.
• W1994855231 cites W1981642161 @default.
• W1994855231 cites W1987854010 @default.
• W1994855231 cites W1988787424 @default.
• W1994855231 cites W2000736649 @default.
• W1994855231 cites W2018450202 @default.
• W1994855231 cites W2031429397 @default.
• W1994855231 cites W2035382067 @default.
• W1994855231 cites W2038204617 @default.
• W1994855231 cites W2042509724 @default.
• W1994855231 cites W2045540294 @default.
• W1994855231 cites W2046475112 @default.
• W1994855231 cites W2046675807 @default.
• W1994855231 cites W2061097390 @default.
• W1994855231 cites W2062725384 @default.
• W1994855231 cites W2069260705 @default.
• W1994855231 cites W2069858536 @default.
• W1994855231 cites W2069891069 @default.
• W1994855231 cites W2094229819 @default.
• W1994855231 cites W2105567764 @default.
• W1994855231 cites W2107118655 @default.
• W1994855231 cites W2108248718 @default.
• W1994855231 cites W2113032467 @default.
• W1994855231 cites W2118387749 @default.
• W1994855231 cites W2118812883 @default.
• W1994855231 cites W2119928714 @default.
• W1994855231 cites W2139996507 @default.
• W1994855231 cites W2145245207 @default.
• W1994855231 cites W2146240002 @default.
• W1994855231 cites W2149001063 @default.
• W1994855231 cites W3006182500 @default.
• W1994855231 cites W4246641585 @default.
• W1994855231 cites W4247621360 @default.
• W1994855231 doi "https://doi.org/10.1016/j.jpba.2008.09.026" @default.
• W1994855231 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18977625" @default.
• W1994855231 hasPublicationYear "2008" @default.
• W1994855231 type Work @default.
• W1994855231 sameAs 1994855231 @default.
• W1994855231 citedByCount "24" @default.
• W1994855231 countsByYear W19948552312012 @default.
• W1994855231 countsByYear W19948552312013 @default.
• W1994855231 countsByYear W19948552312015 @default.
• W1994855231 countsByYear W19948552312016 @default.
• W1994855231 countsByYear W19948552312017 @default.
• W1994855231 countsByYear W19948552312022 @default.
• W1994855231 crossrefType "journal-article" @default.
• W1994855231 hasAuthorship W1994855231A5022502699 @default.
• W1994855231 hasAuthorship W1994855231A5067344128 @default.
• W1994855231 hasConcept C137535248 @default.
• W1994855231 hasConcept C159654299 @default.
• W1994855231 hasConcept C170493617 @default.
• W1994855231 hasConcept C185592680 @default.
• W1994855231 hasConcept C203014093 @default.
• W1994855231 hasConcept C2780035454 @default.
• W1994855231 hasConcept C2780420688 @default.
• W1994855231 hasConcept C2780426850 @default.
• W1994855231 hasConcept C2781197716 @default.
• W1994855231 hasConcept C43617362 @default.
• W1994855231 hasConcept C55493867 @default.
• W1994855231 hasConcept C64903051 @default.
• W1994855231 hasConcept C70721500 @default.
• W1994855231 hasConcept C71924100 @default.
• W1994855231 hasConcept C86803240 @default.
• W1994855231 hasConcept C88045685 @default.
• W1994855231 hasConcept C98274493 @default.
• W1994855231 hasConceptScore W1994855231C137535248 @default.
• W1994855231 hasConceptScore W1994855231C159654299 @default.
• W1994855231 hasConceptScore W1994855231C170493617 @default.
• W1994855231 hasConceptScore W1994855231C185592680 @default.
• W1994855231 hasConceptScore W1994855231C203014093 @default.
• W1994855231 hasConceptScore W1994855231C2780035454 @default.
• W1994855231 hasConceptScore W1994855231C2780420688 @default.
• W1994855231 hasConceptScore W1994855231C2780426850 @default.
• W1994855231 hasConceptScore W1994855231C2781197716 @default.
• W1994855231 hasConceptScore W1994855231C43617362 @default.
• W1994855231 hasConceptScore W1994855231C55493867 @default.
• W1994855231 hasConceptScore W1994855231C64903051 @default.
• W1994855231 hasConceptScore W1994855231C70721500 @default.
• W1994855231 hasConceptScore W1994855231C71924100 @default.
• W1994855231 hasConceptScore W1994855231C86803240 @default.
• W1994855231 hasConceptScore W1994855231C88045685 @default.
• W1994855231 hasConceptScore W1994855231C98274493 @default.
• W1994855231 hasIssue "5" @default.
• W1994855231 hasLocation W19948552311 @default.
• W1994855231 hasLocation W19948552312 @default.
• W1994855231 hasOpenAccess W1994855231 @default.
• W1994855231 hasPrimaryLocation W19948552311 @default.
• W1994855231 hasRelatedWork W1603416295 @default.
• W1994855231 hasRelatedWork W1959407146 @default.
• W1994855231 hasRelatedWork W1988861809 @default.
• W1994855231 hasRelatedWork W1994855231 @default.
• W1994855231 hasRelatedWork W2017409119 @default.

• next